<PAGE>
                                                                   Exhibit 10.83


                               RESEARCH AGREEMENT

MADE AND ENTERED THIS 19 DAY OF NOVEMBER 2002 BY AND BETWEEN ADVANCED VIRAL
RESEARCH CORPORATION INC. WHOSE ADDRESS IS 200 CORPORATE BOULEVARD SO., YONKERS,
NY 10701 USA (HEREINAFTER: "THE COMPANY") AND KAPLAN MEDICAL CENTER (MEDICAL
RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND) WHOSE ADDRESS IS,
P.O. BOX 1, REHOVOT 76100, ISRAEL (HEREINAFTER: "THE FUND")

WHEREAS: The Company wishes to carry out a study of a Phase I/I Trial of the
         Peptide Nucleic Acid Complex Product R in Patients with Advanced-Stage
         Acquired Imminodeficiency Syndrome Study (hereinafter: "THE STUDY") in
         accordance with the Study Protocol (hereinafter: "THE STUDY PROTOCOL")
         dated March 10, 2002 attached to this Agreement as Schedule A and
         constituting an integral part thereof; AND

WHEREAS: The Fund, through the services of Prof. Zev M. Shtoeger (hereinafter:
         "THE INVESTIGATOR") of the Kaplan Medical Center (hereinafter: "THE
         HOSPITAL") agrees to carry out the study on behalf of the Company; AND

WHEREAS: The parties to this Agreement agree to comply with the terms specified
         in the appendix to the Guidelines of the Ministry of Health Committee
         for Research Contracts with Commercial Companies No. 15/98 dated
         16/11/98 titled "Obligations of the Commercial Company" attached to
         this agreement as SCHEDULE B and constituting an integral part thereof
         (hereinafter: "THE MINISTRY GUIDELINES");

WHEREAS: The Company, the Fund, the Hospital and the Investigator all
         acknowledge and accept the fact that a principal purpose of the Study
         is to produce results for submission to the U.S.F.D.A. in support of a
         new drug application for a New Drug Approval (NDA) from said U.S.F.D.A.
         and for that reason, the study must be performed in compliance with all
         relevant laws and regulations of the U.S. and of the State of Israel.

NOW, THEREFOR. IT IS AGREED AND STIPULATED BETWEEN THE PARTIES AS FOLLOWS:

1.       THE PREAMBLE

         1.1.     The Preamble to this Research Agreement and all its addenda
                  constitute an integral part thereof.

         1.2.     It is a condition precedent to the validity of this Research
                  Agreement that this Agreement shall come into effect only
                  after approval is received from the Helsinki Committee and the
                  Ministry of Health Committee for Research Contracts with
                  Commercial Companies.



<PAGE>

2.       THE STUDY

         2.1.     The Fund undertakes to perform the Study, using the services
                  of the Investigator, in accordance with the Study Protocol,
                  the Ministry of Health instructions, the terms specified in
                  the approval of the Helsinki Committee, current good clinical
                  practice and the statutes and regulations of the State of
                  Israel including its Ministry of Health and of the United
                  States including its Food and Drug Administration (FDA).
                  Should any contradiction arise between the above, the
                  instructions of the Ministry of Health and the tents specified
                  in the approval of the Helsinki Committee will prevail.
                  Whenever applicable, the Study will be performed only after
                  approval of the Study Protocol by the Helsinki Committee.

         2.2.     The Fund will conduct the Study in accordance with Section 2.1
                  above and according to all written instructions and
                  prescriptions issued by the Company and governing the
                  administration of the Study's drug. All Study drugs and
                  medicaments will be supplied by the Company at its sole
                  expense. The Fund shall maintain proper records concerning the
                  administration of the Study's drug.

         2.3.     The Study will be conducted in a manner required of a
                  reasonable and prudent clinical investigator or physician.

         2.4.     In the course of the Study, the Fund will also comply with the
                  Biomedical Research Manual which is applicable in Israel.

3.       REPORTS AND PUBLICATIONS

         3.1.     The Fund agrees to permit representatives of the Company to
                  examine its facilities in order to determine their adequacy,
                  validate case reports against original data in its files and
                  monitor work performed to insure its compliance with the Study
                  Protocol and the relevant guidelines stipulated in the
                  Biomedical Research Manual. All Company's activities will be
                  conducted at reasonable times and in a reasonable manner.

         3.2.     Publication of the Study results in scientific literature is
                  encouraged, but the Company reserves the right to review any
                  paper written utilizing data generated from the Study before
                  such paper is presented or submitted for publication and to
                  stay publication for at least six (6) months in its
                  discretion.

         3.3.     The Company undertakes to comply with the terms concerning
                  publications, which are specified in paragraphs 1-- 5 to the
                  Ministry Guidelines (Schedule B).



                                       2
<PAGE>

4.       CONFIDENTIALITY AND PROPRIETARY RIGHTS

         4.1.     All information designated by the Company as confidential and
                  obtained by the Fund and/or its assistants from the Company in
                  connection with the Study (hereinafter: "The Confidential
                  Information") shall be treated as confidential both during the
                  Study and for a period of three (3) years following its
                  termination. The Confidential Information shall not be
                  disclosed to any third party without prior written approval
                  from the Company, except f requested by law and/or court order
                  and/or the FDA or any national regulatory health authority.
                  This restriction shall not apply to Confidential Information
                  which is, or becomes, public domain through no fault of the
                  Fund, the Hospital or the Investigator and/or was obtained by
                  the Fund and/or by the Investigator from another source as
                  proved by documentary evidence.

         4.2.     The parties undertake to maintain the confidentiality of all
                  details relating to the patients participating in the Study.
                  It is hereby agreed that the Fund shall not release any
                  details of the identity of the patients and the Company
                  undertakes that if for any reason whatsoever, it should become
                  privy to such details, it shall maintain them in strict
                  confidentiality.

         4.3.     With the exception of personal and confidential medical
                  records, all data generated during the course of the Study
                  will become the property of the Company and shall not be
                  disclosed to any third party without the prior written
                  approval of the Company.

         4.4.     Any inventions or discoveries made by the Fund during the
                  course of the Study relating to use of the drug under study
                  shall be disclosed to the Company and shall become its
                  property. All other inventions developed by the Fund and/or
                  the Hospital under this study shall remain and/or become the
                  property of the Hospital. The Fund, the Hospital and the
                  Investigator will cooperate fully with the Company in any and
                  all of its efforts to obtain patents and to enforce said
                  patents throughout the world, without payment to the Fund, the
                  Hospital or the Investigator but entirely at the expense of
                  the Company.

5.       TERM AND TERMINATION

         5.1.     The term of this Agreement shall be from the date of its
                  execution by the last party (subject to approval as
                  conditioned in clause 1.2 above, whichever is later) until the
                  Study is either completed according to the Study Protocol or
                  terminated. It is anticipated that this study should be
                  completed by June 1, 2003.



                                       3
<PAGE>

         5.2.     The Company retains the right to terminate this study for good
                  and sufficient reasons at any time subject to thirty (30) days
                  prior written notice. In the event early termination occurs,
                  the costs of non-cancelable items shall be paid by the Company
                  and payment of the agreed Remuneration shall be prorated
                  according to Article 6.

6.       REMUNERATION

         6.1.     In return for the Fund's performance of the Study, the Company
                  undertakes to pay the Fund U.S. Dollars minimum of $105,000 up
                  to a maximum of $210,000 (hereinafter: "The Remuneration")
                  according to the payment schedule listed in Schedule C
                  attached o this Agreement and constituting an integral part
                  thereof.

         6.2.     The Fund shall provide the Company with a receipt for each
                  installment paid.

7.       CLAIMS, LIABILITY AND INSURANCE

Subject to the fulfillment of the Fund's undertakings stated in paragraph 2
supra:

         7.1.     The Company shall bear sole responsibility and bear any
                  payment and/or compensation and/or liability for any damage
                  whatsoever caused to any person, directly or indirectly, as a
                  result of the performance of the Study, but only up to the
                  limits of insurance coverage obtained by the Company for this
                  purpose, as set forth in Schedule 0 annexed hereto.

         7.2.     The Company shall pay all expenses associated with any
                  proceedings taking place as a result of a complaint and/or
                  legal claim submitted by any person in respect of damages
                  claimed to have been caused as a result of the performance of
                  the Study. Whenever applicable, the Company shall immediately
                  indemnify the Fund and/or the Hospital and/or the State of
                  Israel and/or any of their employees and/or their agents
                  and/or their representatives and/or the Investigator for any
                  such expenses paid, together with attachment differences, but
                  only up to the limits of insurance coverage obtained by the
                  Company for this purpose, as set forth in Schedule I annexed
                  hereto.

         7.3.     The Fund will notify the Company, within 20 working days from
                  the day the Fund acquired such knowledge, of any complaint,
                  claim, or injury relating to the Study.

         7.4.     Without derogating from its above liabilities, the Company
                  shall cover the medical personnel conducting the Study, the
                  Fund and the Hospital (hereinafter: "The Beneficiaries") with
                  an insurance policy, for an amount similar to the amount with
                  which the State of Israel insures its physicians,




                                       4
<PAGE>

                  against third party's claims and/or demands associated with
                  the performance of the Study.

8.       ADVERSE EFFECTS

         8.1.     In the event one or more of the participating patients sustain
                  any adverse effects related to the Study, the Investigator
                  shall inform the Company and/or the Hospital's Helsinki
                  Committee and/or the Hospital management and/or the authorized
                  national health authorities. The Investigator and the Fund are
                  also entitled to immediately cease the performance of the
                  Study and report their decision to the Company.

         8.2.     In the aforementioned event, the Company undertakes to break
                  the study medications code and immediately inform the
                  Investigator and/or the Fund the content of the medication
                  received by each participating patient. The Company will also
                  immediately take all measures at its disposal, to evaluate the
                  risk to the other patients and will instruct the Investigator
                  which measures to take in regard to that risk.

9.       LAW AND VENUE

         Any dispute between the parties to this Agreement, including its breach
         and/or its implementation and/or its termination, shall be decided
         exclusively by the competent court of law in Tel-Aviv, Israel which
         shall have exclusive jurisdiction and the law that shall apply in such
         case shall be the statutes and laws of the State of Israel.

10.      MISCELLANEOUS

         10.1.    NON EMPLOYMENT. For the purpose of this Agreement, the Fund
                  and/or its servants and/or investigators will be deemed an
                  independent contractor and not an employee of the Company.

         10.2.    GOOD FAITH. Both parties shall be under a duty to act in good
                  faith in the performance and enforcement of this Agreement.

         10.3.    NOTICES. Except as otherwise provided in this Agreement, all
                  notices permitted or required by this Agreement shall be in
                  writing and shall be deemed to have been duly served (I) upon
                  personal delivery (ii) upon facsimile transmission (receipt of
                  which has been orally confirmed by the recipient) or (iii)
                  Seven (7) business days after deposit, postage prepaid, return
                  receipt requested, if eth by Registered Mail and addressed to
                  the address of the parties first above stated or in accordance
                  with such other address information as the party to receive
                  notice may provide in writing to the other party in accordance
                  with the above notice provisions. Any



                                       5
<PAGE>

                  notice given by any other method will be deemed to have been
                  duly served upon receipt thereof.

         10.4.    ASSIGNMENT. This Agreement is personal to the parties and may
                  not be assigned without the prior written consent of the other
                  party.

         10.5.    CAPTIONS. Any paragraph or other captions are inserted for
                  convenience only and shall not be considered a part of or
                  affect the interpretation or construction of any of the
                  provisions of this Agreement.

         10.6.    WAIVERS. No course of dealing in respect of, nor any omission
                  or delay in the exercise of, any right, power, or privilege by
                  either party shall operate as a waiver thereof, nor shall any
                  single or partial exercise thereof preclude any further or
                  other exercise thereof or of any other, as each such right,
                  power, or privilege may be exercised either independently or
                  concurrently with others and as often and in such order as
                  each party may deem expedient.

         10.7.    SURVIVAL OF PROVISIONS. Notwithstanding termination of this
                  Agreement for any reason, this Agreement shall remain in full
                  force and effect with respect to the parties undertakings
                  related to the Study and to the provisions of Article 4 which
                  shall survive any such termination.

         10.8.    ENTIRE AGREEMENT; AMENDMENTS. This Agreement, including,
                  without limitation, its schedules, contains the entire
                  agreement of the parties with respect to its subject matter.
                  No oral or prior written statements or representations not
                  incorporated herein shall have any force or effect, nor shall
                  any part of this Agreement be amended, supplemented, waived or
                  otherwise modified except in a writing signed by both parties.

         10.9.    SEVERABILITY. If any provision of this Agreement is determined
                  by a court of competent jurisdiction to be invalid, illegal,
                  or unenforceable, that determination shall not affect any
                  other provision of this Agreement, and each such other
                  provision shall be construed and enforced as if the invalid,
                  illegal, or unenforceable provision were not contained herein.

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly
executed and each of the undersigned hereby warrants and represents that he or
she has been and is, on the date of this Agreement, duly authorized by all
necessary and appropriate action to execute this Agreement.


                                       /s/ Kaplan Medical Center
                                       Affiliated to the Hebrew University
/s/ SHALOM Z. HIRSCHMAN, MD            MEDICAL SCHOOL AND HADASSAH
--------------------------------       -----------------------------------------
         The Company                              The Fund




                                       6
<PAGE>

I the undersigned Zev M Shtoeger hereby declare and confirm that I read and
understood the Agreement, I agree to be appointed as the Investigator of the
Study on behalf of the Fund, and I undertake to comply with all the conditions,
provisions, instructions and stipulations of the Agreement.


                  /s/ ZEV M. SHTOEGER
                  --------------------------
                  The Investigator



                                       7